Key result
A treat and repair strategy with aggressive PAH therapies before surgical correction resulted in normalization of pulmonary vascular resistance in 2 patients with complex congenital heart disease.
Why the study?
Does a treat and repair strategy with aggressive PAH therapies allow for successful surgical correction in patients with complex congenital heart disease and advanced PVD?
Case Report (n=2)
Does a treat and repair strategy with aggressive PAH therapies allow for successful surgical correction in patients with complex congenital heart disease and advanced PVD?
A treat and repair strategy using aggressive PAH therapies before surgery may allow for successful surgical correction in select patients with complex congenital heart disease and advanced PVD previously considered inoperable.
Answers are grounded in this paper and cite their sources.
Case report on inoperable CHD-PAH leaves open optimal timing for advanced therapies; prospective studies required.
Pulmonary arterial hypertension (PAH) is a frequent complication of congenital heart disease as a consequence of altered pulmonary hemodynamics with increased pulmonary blood flow and pressure. The development of pulmonary vascular disease (PVD) in this patient population is an important concern in determining operative strategy. Early, definitive surgical repair, when possible, is the best therapy to prevent and treat PVD. However, this is not possible in some patients because they either presented late, after the development of PVD, or they have complex lesions not amenable to one-step surgical correction, including patients with single ventricle physiology, who have a continuing risk of developing PVD. These patients represent an important, high-risk subgroup and many have been considered inoperable. We present a case series of two patients with complex congenital heart disease and advanced PVD who successfully underwent a treat and repair strategy with aggressive PAH therapies before surgical correction. Both patients had normalization of pulmonary vascular resistance prior to surgical correction. Caution is warranted in applying this strategy broadly and long-term follow-up for these patients is crucial. However, this treat and repair strategy may allow for favorable outcomes among some patients who previously had no therapeutic options.
No takes yet. Share an insight, caveat, or question.
Kameny et al. (2017) conducted a case report in Advanced pulmonary hypertension associated with congenital heart disease (n=2). Treat and repair strategy with aggressive PAH therapies before surgical correction was evaluated on Normalization of pulmonary vascular resistance. A treat and repair strategy with aggressive PAH therapies before surgical correction resulted in normalization of pulmonary vascular resistance in 2 patients with complex congenital heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: